SB-649868
Chemical compound
- None
- Investigational
- N-([(2S)-1-([5-(4-fluorophenyl)-2-methyl-4-thiazolyl]carbonyl)-2-piperidinyl]methyl)-4-benzofurancarboxamide
- 380899-24-1
Y
- 25195495
- 25069706
- 1L1V1K2M4V
- ChEMBL1272307
- DTXSID90191491
- Interactive image
- CC1=NC(=C(S1)C2=CC=C(C=C2)F)C(=O)N3CCCC[C@H]3CNC(=O)C4=C5C=COC5=CC=C4
InChI
- InChI=1S/C26H24FN3O3S/c1-16-29-23(24(34-16)17-8-10-18(27)11-9-17)26(32)30-13-3-2-5-19(30)15-28-25(31)21-6-4-7-22-20(21)12-14-33-22/h4,6-12,14,19H,2-3,5,13,15H2,1H3,(H,28,31)/t19-/m0/s1
- Key:ZJXIUGNEAIHSBI-IBGZPJMESA-N
SB-649868 is a dual orexin receptor antagonist that was being developed by GlaxoSmithKline as a treatment for insomnia.[1]
A phase I clinical trial evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse effects.[2] In randomized, double-blind, placebo-controlled crossover trials, the 10 and 30 mg doses increased sleep time and reduced sleep latency.[3] The subsequent phase II study added a 60 mg dose and observed dose-dependent sleep promotion.[4]
The compound no longer appears to be under active development, with the last study posted to ClinicalTrials.gov completed in 2010.
See also
References
- ^ Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, et al. (February 2011). "Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans". Drug Metabolism and Disposition. 39 (2): 215–27. doi:10.1124/dmd.110.035386. PMID 21045199. S2CID 1995624.
- ^ Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, et al. (August 2012). "Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist". Journal of Psychopharmacology. 26 (8): 1058–70. doi:10.1177/0269881111408954. PMID 21730017. S2CID 29578953.
- ^ Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ (April 2012). "Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia". Neuropsychopharmacology. 37 (5): 1224–33. doi:10.1038/npp.2011.310. PMC 3306884. PMID 22237311.
- ^ Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E (August 2012). "The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia". Sleep. 35 (8): 1097–104. doi:10.5665/sleep.1996. PMC 3397789. PMID 22851805.
Further reading
- Ratti E (December 13, 2007). "Psychiatry: An Innovative Drug Discovery Pipeline" (PDF) (GSK Neurosciences seminar). Archived from the original on December 5, 2008.
- Scammell TE, Winrow CJ (February 2011). "Orexin receptors: pharmacology and therapeutic opportunities". Annual Review of Pharmacology and Toxicology. 51: 243–66. doi:10.1146/annurev-pharmtox-010510-100528. PMC 3058259. PMID 21034217.
- v
- t
- e
- Antagonists: ACT-335827
- ACT-462206
- Almorexant
- AZD-4041
- C4X-3256 (INDV-2000)
- CR-5542
- CVN-766
- Daridorexant
- Fazamorexant (YZJ-1139)
- Filorexant
- GSK-649868 (SB-649868)
- Lemborexant
- Nivasorexant (ACT-539313)
- RTIOX-276
- SB-334867
- SB-408124
- Suvorexant
- TCS-1102
- Tebideutorexant (JNJ-61393215)
- Vornorexant (ORN-0829, TS-142)
- Agonists: AEX-19
- ALKS-2680
- Danavorexton (TAK-925)
- E-2086
- Firazorexton (TAK-994)
- Orexin (A, B)
- Oveporexton
- SB-668875
- Suntinorexton (TAK-861)
- Antagonists: ACT-335827
- ACT-462206
- Almorexant
- Daridorexant
- EMPA
- Fazamorexant (YZJ-1139)
- Filorexant
- GSK-649868 (SB-649868)
- JNJ-10397049
- Lemborexant
- MK-1064
- MK-3697
- MK-8133
- Seltorexant
- Suvorexant
- TCS-1102
- TCS-OX2-29
- Vornorexant (ORN-0829, TS-142)
![]() | This sedative-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e